secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organogenesis Holdings Inc. (ORGO)
CIK:        0001661181
Form:       8-K
Filed at:   2022-03-01T23:59:59+00:00
Accession:  0001193125-22-061346
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organogenesis Q4 revenue $128.6M (+20% YoY), FY22 guidance $485M-$515M
----------------------------------------------------------------------

- Q4 net revenue $128.6M (up 20% YoY); Advanced Wound Care $121.4M (+30%), Surgical & Sports Medicine $7.2M (-45%).
- Q4 GAAP net income $51.7M ($0.39 diluted EPS) vs $18.3M ($0.15) a year ago; adjusted EBITDA $26.3M.
- FY2021 net revenue $468.1M (+38% YoY); net income $94.9M ($0.71 diluted EPS); adjusted EBITDA $89.1M.
- FY2022 guidance: net revenue $485M-$515M (+4% to +10% YoY); net income $56.5M-$71.5M; adjusted EBITDA $79.9M-$95.3M.
- Cash and equivalents $114.5M; total debt $73.6M as of Dec 31, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661181/000119312522061346/0001193125-22-061346-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661181/000119312522061346/d325515d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-061346

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer